Institut Neuropsychiatricke Pece (INEP)
- Address
- Křižíkova 264/22, 186 00 Prague, Czechia
Institut Neuropsychiatricke Pece (INEP)
Institut Neuropsychiatricke Pece (INEP) is a specialized neuropsychiatric research facility with demonstrated expertise in conducting clinical trials for neurological conditions. The institute focuses on investigating innovative therapeutic approaches for complex neurological disorders, with particular emphasis on developing and evaluating novel preventive treatments.
- Migraine prevention and episodic migraine management
- Neurological headache disorders and therapeutic interventions
- Safety and efficacy evaluation of emerging biologics for neurological conditions
The center's research portfolio includes pivotal studies examining preventive treatments for episodic migraine, utilizing advanced methodologies to assess both safety and efficacy outcomes. With a commitment to advancing neuropsychiatric care, INEP contributes to the development of innovative pharmacological interventions designed to reduce the burden of chronic neurological conditions and improve patient quality of life through evidence-based therapeutic solutions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut Neuropsychiatricke Pece (INEP)
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of the Safety and Efficacy of Subcutaneous MEDI0618 in Reducing Migraine Headache Days in Adults with Episodic Migraine: A Randomized, Double-Blind Study | AbbVie Deutschland GmbH & Co. KG | Phase II | Recruiting | Dec 2025 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Medi0618 | 1 | Unknown | 2025-12-10 | 2025-12-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.